Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316217 | 0.87 | CHRNB2 (0.36) | CHRNB2CHRNA4DRD2DRD1HTR2C | |
| SCHEMBL26620745 | 0.78 | HTR2C (0.42) | CHRNB2CHRNA4DRD2DRD1HTR2C | |
| SCHEMBL24469640 | 0.77 | CCNA2 (0.34) | CHRNB2CHRNA4DRD2DRD1 | |
| SCHEMBL12898368 | 0.76 | MEN1 (0.51) | HTR2CHTR2BHTR2A | |
| SCHEMBL1615703 | 0.75 | CDC7 (0.38) | CHRNB2CHRNA4CDC7 | |
| SCHEMBL25516801 | 0.75 | SIGMAR1 (0.38) | CHRNB2CHRNA4DRD2DRD1HTR2C | |
| SCHEMBL10297581 | 0.75 | SIGMAR1 (0.38) | CHRNB2CHRNA4DRD2DRD1HTR2C | |
| SCHEMBL8225223 | 0.72 | CHRNB2 (0.46) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL24742538 | 0.71 | AAK1 (0.32) | SIGMAR1 | |
| SCHEMBL27010853 | 0.70 | HTR2C (0.30) | HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CHRNB2 2746/4885CHRNA4 3610/4885DRD2 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.